A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients

Authors: Ding, P.y-A.¹; Chu, K-M.²; Chiang, H-T.³; Shu, K-H.⁴

Source: International Journal of Clinical Practice, Volume 58, Supplement 145, December 2004 , pp. 16-22(7)

Abstract:

Summary

Ambulatory blood pressure monitoring (ABPM) was used to compare the efficacy and tolerability of once-daily telmisartan 40 mg and once-daily losartan 50 mg in Taiwanese patients with mild-to-moderate essential hypertension in a randomised, double-blind, double-dummy, parallel-group study. The initial 2-week placebo run-in phase was followed by randomisation to treatment with telmisartan 40 mg (n = 31) or losartan 50 mg (n = 30) for 6 weeks. The reduction in 18- to 24-h mean (SE) ambulatory diastolic blood pressure (DBP) from baseline was significantly greater with telmisartan 40 mg (−12.1 ± 1.6 mmHg, p = 0.036) than with losartan 50 mg (−7.0 ± 1.8 mmHg). The reduction in 18- to 24-h mean (SE) ambulatory systolic blood pressure (SBP) from baseline was also greater with telmisartan 40 mg (−16.0 ± 2.4 mmHg) than with losartan 50 mg (−11.8 ± 2.7 mmHg), but did not achieve statistical significance. Telmisartan was well tolerated; no serious adverse events occurred.

Keywords: Telmisartan; losartan; angiotensin II receptor blockers; ambulatory blood pressure monitoring; antihypertensives; hypertension

Document Type: Research article

DOI: 10.1111/j.1742-1241.2004.00405.x

Affiliations: 1: Veterans General Hospital, Taipei 2: Tri-Service General Hospital, Taipei 3: Veterans General Hospital, Kaohsiung 4: Veterans General Hospital, Taichung, Taiwan

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax Refund Policy